OQS
CRDF icon

Occudo Quantitative Strategies’s Cardiff Oncology CRDF Stock Holding History

Occudo Quantitative Strategies’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,566
Closed -$32.3K – 756
2024
Q2 		$32.3K Buy
+14,566
New +$54.9K 0.01% 710

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Occudo Quantitative Strategies's CRDF Position: Q3 2024 in Review

Occudo Quantitative Strategies sold out of Cardiff Oncology (CRDF) in Q3 2024, closing a stake of 14,566 shares — an estimated $32.3K sold.

Occudo Quantitative Strategies first reported a position in CRDF in Q2 2024 and held it in 1 quarter. The position peaked at $32.3K in Q2 2024. 83 funds tracked by Wall St. Rank hold CRDF as of Q3 2024.

  • Occudo Quantitative Strategies reported no remaining Cardiff Oncology position as of Q3 2024 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 14,566 Cardiff Oncology shares in Q3 2024, an estimated $32.3K.
  • Occudo Quantitative Strategies first reported a position in Cardiff Oncology in Q2 2024 and held it in 1 quarter.
  • Occudo Quantitative Strategies's Cardiff Oncology position peaked at $32.3K in Q2 2024.
  • 83 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2024.

Based on Occudo Quantitative Strategies's 13F filing for Q3 2024, filed 14 Nov 2024.